We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Cronos Group (CRON - Free Report) closed at $12.10, marking a +0.83% move from the previous day. This change outpaced the S&P 500's 0.19% gain on the day. At the same time, the Dow lost 0.23%, and the tech-heavy Nasdaq gained 0.27%.
Coming into today, shares of the cannabis company had gained 96.56% in the past month. In that same time, the Finance sector lost 1.13%, while the S&P 500 gained 0.74%.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be November 26, 2018. In that report, analysts expect CRON to post earnings of $0.01 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.29 million, up 975.24% from the year-ago period.
CRON's full-year Zacks Consensus Estimates are calling for earnings of -$0.02 per share and revenue of $23.87 million. These results would represent year-over-year changes of -300% and +649.69%, respectively.
Investors might also notice recent changes to analyst estimates for CRON. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 50% lower within the past month. CRON is currently sporting a Zacks Rank of #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This group has a Zacks Industry Rank of 183, putting it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Cronos Group (CRON - Free Report) closed at $12.10, marking a +0.83% move from the previous day. This change outpaced the S&P 500's 0.19% gain on the day. At the same time, the Dow lost 0.23%, and the tech-heavy Nasdaq gained 0.27%.
Coming into today, shares of the cannabis company had gained 96.56% in the past month. In that same time, the Finance sector lost 1.13%, while the S&P 500 gained 0.74%.
CRON will be looking to display strength as it nears its next earnings release, which is expected to be November 26, 2018. In that report, analysts expect CRON to post earnings of $0.01 per share. This would mark no growth from the year-ago period. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.29 million, up 975.24% from the year-ago period.
CRON's full-year Zacks Consensus Estimates are calling for earnings of -$0.02 per share and revenue of $23.87 million. These results would represent year-over-year changes of -300% and +649.69%, respectively.
Investors might also notice recent changes to analyst estimates for CRON. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 50% lower within the past month. CRON is currently sporting a Zacks Rank of #3 (Hold).
The Financial - Investment Management industry is part of the Finance sector. This group has a Zacks Industry Rank of 183, putting it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.